Atea Pharmaceuticals (AVIR) Other Working Capital Changes (2019 - 2026)

Atea Pharmaceuticals' Other Working Capital Changes history runs 6 years deep, the most recent figure standing at -$53000.0 for Q1 2026.

• In Q1 2026, Other Working Capital Changes fell 12.77% year-over-year to -$53000.0; the TTM figure through Mar 2026 stood at -$196000.0 (down 10.11% YoY), while the FY2025 annual figure was -$190000.0, down 8.57% from the prior year.
• Other Working Capital Changes for Q1 2026 stood at -$53000.0, down from -$47000.0 in the prior quarter.
• The five-year high for Other Working Capital Changes was $8.5 million in Q3 2024, with the low at -$6.2 million in Q4 2024.
• The 5-year median for Other Working Capital Changes is -$88000.0 (2026), against an average of $181764.7.
• The sharpest annual moves came in 2022 and 2023: Other Working Capital Changes soared 99.98% in 2022, then decreased 17.14% in 2023.
• Atea Pharmaceuticals' Other Working Capital Changes stood at -$35000.0 in 2022, then dropped by 17.14% to -$41000.0 in 2023, then fell by 9.76% to -$45000.0 in 2024, then retreated by 4.44% to -$47000.0 in 2025, then dropped by 12.77% to -$53000.0 in 2026.
• Business Quant data shows AVIR's Other Working Capital Changes at -$53000.0 in Q1 2026, -$47000.0 in Q4 2025, and -$48000.0 in Q3 2025.